The trials and tribulations in the drug discovery cycle: A particular case for Alzheimer’s disease

The trials and tribulations in the drug discovery cycle

As people live longer lives, the spectre of Alzheimer’s disease will only grow. Scientists now know that the amyloid beta (Aβ) peptides are important for treating Alzheimer’s, particularly Aβ42 which aggregates into the amyloid plaques that trigger the disease. Researchers have been looking to target γ-secretase – the enzyme that creates pathogenic Aβ42 affecting the relative abundance of short Aβ […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION